X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
OA-201 consists of a natural metabolite, formulated as an injectable small molecule product. It is being developed for the treatment of symptomatic osteoarthritis pain.
Lead Product(s): OA-201
Therapeutic Area: Musculoskeletal Product Name: OA-201
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
Under the agreement, Ascendia will provide services to support the clinical development of OA-201, a novel, injectable small molecule therapeutic for the treatment of symptomatic osteoarthritis pain.
Lead Product(s): OA-201
Therapeutic Area: Musculoskeletal Product Name: OA-201
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Ascendia Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 05, 2023
Details:
Ampion (Aspartyl-alanyl-diketopiperazine) is a novel biologic drug containing a blood-derived cyclized peptide and small molecules that target multiple pathways in the innate immune response characteristic of inflammatory disease.
Lead Product(s): Aspartyl-alanyl-diketopiperazine
Therapeutic Area: Musculoskeletal Product Name: Ampion
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2022
Details:
Ampion, a novel biologic drug containing a blood-derived cyclized peptide, demonstrated a statistically significant reduction in pain and trended favorably toward improvement in function versus saline control, retained more than 85% power to evaluate improvements in pain.
Lead Product(s): Aspartyl-alanyl-diketopiperazine
Therapeutic Area: Rheumatology Product Name: Ampion
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2022
Details:
AP-019 utilizing inhaled Ampion™ to treat those suffering from respiratory distress due to COVID-19. Ampion is immunomodulatory agent with anti-inflammatory effects, Ampion interrupts the hyperactive immune response associated with COVID-19.
Lead Product(s): Aspartyl-alanyl-diketopiperazine
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampion
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2021
Details:
Ampio’s poster highlights the Company’s recently completed AP-014 Phase I clinical trial utilizing an inhaled form of Ampio’s drug, Ampion, for treatment of respiratory distress in patients as a result of COVID-19.
Lead Product(s): Aspartyl-alanyl-diketopiperazine
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampion
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2021
Details:
AP-014 Phase I clinical trial utilizing an inhaled form of Ampio's drug, Ampion™, in treating respiratory distress in patients as a result of COVID-19.
Lead Product(s): Aspartyl-alanyl-diketopiperazine
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampion
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2021
Details:
Ampio has received Investigational Review Board (IRB) approval to conduct a Phase 1 study that will evaluate the safety and efficacy of Ampion in patients with prolonged respiratory symptoms due to COVID-19 (Long-COVID).
Lead Product(s): Aspartyl-alanyl-diketopiperazine
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampion
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2021
Details:
Phase I trial of inhaled Ampion in COVID-19 respiratory distress meets primary endpoint, achieves better reduction in all-cause mortality than in interim analysis.
Lead Product(s): Aspartyl-alanyl-diketopiperazine
Therapeutic Area: Musculoskeletal Product Name: Ampion
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2021
Details:
Laboratory results suggest Ampion's suitability for addressing kidney diseases and provides further evidence it is a platform biologic for treatment of inflammatory and autoimmune diseases.
Lead Product(s): Aspartyl-alanyl-diketopiperazine
Therapeutic Area: Infections and Infectious Diseases Product Name: Ampion
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
